Lentiviral vectors: A versatile tool to fight cancer

Current Molecular Medicine

Volumn 13, Issue 4, 2013, Pages 602-625

  Emeagi, P U ^a   Goyvaerts, C ^a   Maenhout, S ^a   Pen, J ^a   Thielemans, K ^a   Breckpot, K ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Cancer; Lentiviral vector; Tumor immunology

Indexed keywords

LENTIVIRUS VECTOR; MITOGEN ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN;

BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CELL DEATH; CYTOKINESIS; DENDRITIC CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; IMMUNOSURVEILLANCE; INFLAMMATION; MUTAGENESIS; NEOPLASM; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; SUICIDE GENE THERAPY; TUMOR CELL; TUMOR IMMUNOLOGY; VIRAL GENE DELIVERY SYSTEM;

GENETIC THERAPY; GENETIC VECTORS; HUMANS; LENTIVIRUS; NEOPLASMS;

EID: 84876708397     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524011313040011     Document Type: Review

References (375)

1. Breckpot K, Aerts JL, Thielemans K. Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther 2007; 14(11): 847-862.
2. Escors D, Breckpot K. Lentiviral vectors in gene therapy: their current status and future potential. Arch Immunol Ther Exp (Warsz) 2010; 58(2): 107-119.
3. Breckpot K, Emeagi PU, Thielemans K. Lentiviral vectors for anti-tumor immunotherapy. Curr Gene Ther 2008; 8(6): 438-448.
4. Thomas S, Stauss HJ, Morris EC. Molecular immunology lessons from therapeutic T-cell receptor gene transfer. Immunology 2010; 129(2): 170-177.
5. Frecha C, Levy C, Cosset FL, et al. Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy. Mol Ther 2010; 18(10): 1748-1757.
6. Pellinen R, Hakkarainen T, Wahlfors T, et al. Cancer cells as targets for lentivirus-mediated gene transfer and gene therapy. Int J Oncol 2004; 25(6): 1753-1762.
7. Negre D, Duisit G, Mangeot PE, et al. Lentiviral vectors derived from simian immunodeficiency virus. Curr Top Microbiol Immunol 2002; 261: 53-74.
8. Poeschla EM. Non-primate lentiviral vectors. Curr Opin Mol Ther 2003; 5(5): 529-540.
9. Loewen N, Barraza R, Whitwam T, et al. FIV Vectors. Methods Mol Biol 2003; 229: 251-271.
10. Curran MA, Kaiser SM, Achacoso PL, et al. Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Mol Ther 2000; 1(1): 31-38.
11. Olsen JC. Gene transfer vectors derived from equine infectious anemia virus. Gene Ther 1998; 5(11): 1481-1487.
12. Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72(11): 8463-8471.
13. Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72(12): 9873-9880.
14. Logan AC, Haas DL, Kafri T, et al. Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration. J Virol 2004; 78(16): 8421-8436.
15. Schambach A, Galla M, Maetzig T, et al. Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. Mol Ther 2007; 15(6): 1167-1173.
16. Arumugam PI, Scholes J, Perelman N, et al. Improved human beta-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element. Mol Ther 2007; 15(10): 1863-1871.
17. Zychlinski D, Schambach A, Modlich U, et al. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 2008; 16(4): 718-725.
18. Kafri T, van Praag H, Gage FH, et al. Lentiviral vectors: regulated gene expression. Mol Ther 2000; 1(6): 516-521.
19. Reiser J, Lai Z, Zhang XY, et al. Development of multigene and regulated lentivirus vectors. J Virol 2000; 74(22): 10589-10599.
20. VandenDriessche T, Thorrez L, Naldini L, et al. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 2002; 100(3): 813-822.
21. Breckpot K, Dullaers M, Bonehill A, et al. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med 2003; 5(8): 654-667.
22. Zufferey R, Nagy D, Mandel RJ, et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15(9): 871-875.
23. Kotsopoulou E, Kim VN, Kingsman AJ, et al. A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J Virol 2000; 74(10): 4839-4852.
24. Biffi A, Bartolomae CC, Cesana D, et al. Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood 2011; 117(20): 5332-5339.
25. Montini E, Cesana D, Schmidt M, et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009; 119(4): 964-975.
26. Wanisch K, Yanez-Munoz RJ. Integration-deficient lentiviral vectors: a slow coming of age. Mol Ther 2009; 17(8): 1316-1332.
27. Cronin J, Zhang XY, Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 2005; 5(4): 387-398.
28. Enkirch T, Kneissl S, Hoyler B, et al. Targeted lentiviral vectors pseudotyped with the Tupaia paramyxovirus glycoproteins. Gene Ther 2013; 20(1): 16-23.
29. Funke S, Schneider IC, Glaser S, et al. Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity. Gene Ther 2009; 16(5): 700-705.
30. Goyvaerts C, De Groeve K, Dingemans J, et al. Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells. Gene Ther 2012; 19(12): 1133-40.
31. Lei Y, Joo KI, Wang P. Engineering fusogenic molecules to achieve targeted transduction of enveloped lentiviral vectors. J Biol Eng 2009; 3: 8.
32. Froelich S, Ziegler L, Stroup K, et al. Targeted gene delivery to CD117-expressing cells in vivo with lentiviral vectors co-displaying stem cell factor and a fusogenic molecule. Biotechnol Bioeng 2009; 104(1): 206-215.
33. Ziegler L, Yang L, Joo K, et al. Targeting lentiviral vectors to antigen-specific immunoglobulins. Hum Gene Ther 2008; 19(9): 861-872.
34. Yang L, Yang H, Rideout K, et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol 2008; 26(3): 326-334.
35. Ageichik A, Buchholz CJ, Collins MK. Lentiviral vectors targeted to MHC II are effective in immunization. Hum Gene Ther 2011; 22(10): 1249-1254.
36. Friedrich RI, Nopora K, Brocker T. Transcriptional targeting of B cells with viral vectors. Eur J Cell Biol 2012; 91(1): 86-96.
37. Leuci V, Gammaitoni L, Capellero S, et al. Efficient transcriptional targeting of human hematopoietic stem cells and blood cell lineages by lentiviral vectors containing the regulatory element of the Wiskott-Aldrich syndrome gene. Stem Cells 2009; 27(11): 2815-2823.
38. Dresch C, Edelmann SL, Marconi P, et al. Lentiviral-mediated transcriptional targeting of dendritic cells for induction of T cell tolerance in vivo. J Immunol 2008; 181(7): 4495-4506.
39. Maatta AM, Korja S, Venhoranta H, et al. Transcriptional targeting of virus-mediated gene transfer by the human hexokinase II promoter. Int J Mol Med 2006; 18(5): 901-908.
40. Kimura T, Koya RC, Anselmi L, et al. Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression. Mol Ther 2007; 15(7): 1390-1399.
41. Breckpot K, Heirman C, Neyns B, et al. Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells. J Gene Med 2004; 6(11): 1175-1188.
42. Howarth JL, Lee YB, Uney JB. Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells). Cell Biol Toxicol 2010; 26(1): 1-20.
43. Nayak S, Herzog RW. Progress and prospects: immune responses to viral vectors. Gene Ther 2010; 17(3): 295-304.
44. Vandendriessche T, Thorrez L, Acosta-Sanchez A, et al. Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost 2007; 5(1): 16-24.
45. Brown BD, Sitia G, Annoni A, et al. In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. Blood 2007; 109(7): 2797-2805.
46. Breckpot K, Escors D, Arce F, et al. HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. J Virol 2010; 84(11): 5627-36.
47. Breckpot K, Emeagi P, Dullaers M, et al. Activation of immature monocyte-derived dendritic cells after transduction with high doses of lentiviral vectors. Hum Gene Ther 2007; 18(6): 536-546.
48. Tan PH, Beutelspacher SC, Xue SA, et al. Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood 2005; 105(10): 3824-3832.
49. Rossetti M, Gregori S, Hauben E, et al. HIV-1-derived lentiviral vectors directly activate plasmacytoid dendritic cells, which in turn induce the maturation of myeloid dendritic cells. Hum Gene Ther 2011; 22(2): 177-188.
50. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357(9255): 539-545.
51. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5): 646-674.
52. Coffelt SB, Lewis CE, Naldini L, et al. Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. Am J Pathol 2010; 176(4): 1564-1576.
53. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420(6917): 860-867.
54. Lin EY, Nguyen AV, Russell RG, et al. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001; 193(6): 727-740.
55. Mantovani A, Allavena P, Sica A. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer 2004; 40(11): 1660-1667.
56. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity 2005; 23(4): 344-346.
57. Breckpot K, Escors D. Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification. Endocr Metab Immune Disord Drug Targets 2009; 9(4): 328-343.
58. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004; 4(1): 11-22.
59. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118(3): 285-296.
60. Umar A, Greenwald P. Alarming colorectal cancer incidence trends: a case for early detection and prevention. Cancer Epidemiol Biomarkers Prev 2009; 18(6): 1672-1673.
61. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol; 11(10): 889-896.
62. Burnet M. Cancer; a biological approach. I. The processes of control. Br Med J 1957; 1(5022): 779-786.
63. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970; 13: 1-27.
64. Ehrlich P. Ueber den jetzigen Stand der Karzinomforschung. Nederlands Tijdschrift voor Geneeskunde, 1909; vol. 5, pp. 273-290.
65. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996; 183(3): 725-729.
66. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997; 9(5): 684-693.
67. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450(7171): 903-907.
68. Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27(12): 3135-3142.
69. Smyth MJ, Thia KY, Street SE, et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000; 191(4): 661-668.
70. Girardi M, Oppenheim DE, Steele CR, et al. Regulation of cutaneous malignancy by gammadelta T cells. Science 2001; 294(5542): 605-609.
71. Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 2011; 7(5): 651-658.
72. Yokoyama WM. Now you see it, now you don't! Nat Immunol 2000; 1(2): 95-97.
73. Bromberg JF, Horvath CM, Wen Z, et al. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci USA 1996; 93(15): 7673-7678.
74. Luster AD, Ravetch JV. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med 1987; 166(4): 1084-1097.
75. Cole KE, Strick CA, Paradis TJ, et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998; 187(12): 2009-2021.
76. Luster AD, Leder P. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 1993; 178(3): 1057-1065.
77. Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002; 13(2): 95-109.
78. Bonehill A, Heirman C, Thielemans K. Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy. J Gene Med 2005; 7(6): 686-695.
79. Egilmez NK, Kilinc MO. Tumor-resident CD8+ T-cell: the critical catalyst in IL-12-mediated reversal of tumor immune suppression. Arch Immunol Ther Exp (Warsz) 2010; 58(6): 399-405.
80. Smyth MJ, Thia KY, Street SE, et al. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 2000; 192(5): 755-760.
81. Takeda K, Smyth MJ, Cretney E, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002; 195(2): 161-169.
82. Takeda K, Okumura K. Current advances and expectations in tumor immunology. Hum Cell 2001; 14(3): 159-163.
83. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3(11): 991-998.
84. Wilczynski JR, Duechler M. How do tumors actively escape from host immunosurveillance? Arch Immunol Ther Exp (Warsz) 2010; 58(6): 435-448.
85. Poggi A, Zocchi MR. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells. Arch Immunol Ther Exp (Warsz) 2006; 54(5): 323-333.
86. Hicklin DJ, Wang Z, Arienti F, et al. Beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest 1998; 101(12): 2720-2729.
87. Seliger B. Different regulation of MHC class I antigen processing components in human tumors. J Immunotoxicol 2008; 5(4): 361-367.
88. Seliger B. Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother 2008; 57(11): 1719-1726.
89. Medema JP, de Jong J, Peltenburg LT, et al. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci USA 2001; 98(20): 11515-11520.
90. van Houdt IS, Oudejans JJ, van den Eertwegh AJ, et al. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma. Clin Cancer Res 2005; 11(17): 6400-6407.
91. Vucic D, Fairbrother WJ. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 2007; 13(20): 5995-6000.
92. Vucic D, Stennicke HR, Pisabarro MT, et al. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 2000; 10(21): 1359-1366.
93. Grossman D, McNiff JM, Li F, et al. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999; 113(6): 1076-1081.
94. Ruttinger D, Li R, Poehlein CH, et al. Increased susceptibility to immune destruction of B16BL6 tumor cells engineered to express a novel pro-Smac fusion protein. J Immunother 2008; 31(1): 43-51.
95. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274(5291): 1363-1366.
96. Ryan AE, Shanahan F, O'Connell J, et al. Addressing the Fas counterattack controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res 2005; 65(21): 9817-9823.
97. Wei S, Shreiner AB, Takeshita N, et al. Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta. Cancer Res 2008; 68(13): 5432-5438.
98. Flavell RA, Sanjabi S, Wrzesinski SH, et al. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 2010; 10(8): 554-567.
99. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005; 8(5): 369-380.
100. Pockaj BA, Basu GD, Pathangey LB, et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol 2004; 11(3): 328-339.
101. Greenhough A, Smartt HJ, Moore AE, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009; 30(3): 377-386.
102. Soliman H, Mediavilla-Varela M, Antonia S. Indoleamine 2,3-dioxygenase: is it an immune suppressor? Cancer J 2010; 16(4): 354-359.
103. Demotte N, Wieers G, Van Der Smissen P, et al. A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res 2010; 70(19): 7476-7488.
104. Mougiakakos D, Johansson CC, Trocme E, et al. Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma. Cancer 2010; 116(9): 2224-2233.
105. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182(8): 4499-4506.
106. Long SA, Buckner JH. CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game. J Immunol 2011; 187(5): 2061-2066.
107. Lourenco EV, La Cava A. Natural regulatory T cells in autoimmunity. Autoimmunity 2011; 44(1): 33-42.
108. Arce F, Breckpot K, Stephenson H, et al. Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis. Arthritis Rheum 2011; 63(1): 84-95.
109. Gershon RK, Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 1970; 18(5): 723-737.
110. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155(3): 1151-1164.
111. Byrne WL, Mills KH, Lederer JA, et al. Targeting regulatory T cells in cancer. Cancer Res 2011; 71(22): 6915-6920.
112. Shevach EM. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 2006; 25(2): 195-201.
113. Bonertz A, Weitz J, Pietsch DH, et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 2009; 119(11): 3311-3321.
114. Jandus C, Bioley G, Dojcinovic D, et al. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. Cancer Res 2009; 69(20): 8085-8093.
115. Correll A, Tuettenberg A, Becker C, et al. Increased regulatory T-cell frequencies in patients with advanced melanoma correlate with a generally impaired T-cell responsiveness and are restored after dendritic cell-based vaccination. Exp Dermatol 2010; 19(8): e213-e221.
116. Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 2007; 13(3): 108-116.
117. Sakaguchi S, Wing K, Onishi Y, et al. Regulatory T cells: how do they suppress immune responses? Int Immunol 2009; 21(10): 1105-1011.
118. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322(5899): 271-275.
119. Tadokoro CE, Shakhar G, Shen S, et al. Regulatory T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivo. J Exp Med 2006; 203(3): 505-511.
120. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008; 9(3):239-244.
121. Jarnicki AG, Lysaght J, Todryk S, et al. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 2006; 177(2): 896-904.
122. Shevach EM, Tran DQ, Davidson TS, et al. The critical contribution of TGF-beta to the induction of Foxp3 expression and regulatory T cell function. Eur J Immunol 2008; 38(4): 915-917.
123. Pandiyan P, Zheng L, Ishihara S, et al. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 2007; 8(12):1353-1362.
124. Aymeric L, Apetoh L, Ghiringhelli F, et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res 2010; 70(3): 855-858.
125. Jonuleit H, Schmitt E, Steinbrink K, et al. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol 2001; 22(7): 394-400.
126. Tan W, Zhang W, Strasner A, et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011; 470(7335):548-553.
127. Mougiakakos D, Choudhury A, Lladser A, et al. Regulatory T cells in cancer. Adv Cancer Res 2010; 107: 57-117.
128. Wilke CM, Wu K, Zhao E, et al. Prognostic significance of regulatory T cells in tumor. Int J Cancer 2010; 127(4): 748-758.
129. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010; 127(4): 759-767.
130. Whelan MC, Casey G, MacConmara M, et al. Effective immunotherapy of weakly immunogenic solid tumours using a combined immunogene therapy and regulatory T-cell inactivation. Cancer Gene Ther 2010; 17(7): 501-511.
131. Klages K, Mayer CT, Lahl K, et al. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res 2010; 70(20): 7788-7799.
132. Rasku MA, Clem AL, Telang S, et al. Transient T cell depletion causes regression of melanoma metastases. J Transl Med 2008; 6: 12.
133. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6(4): 295-307.
134. Marigo I, Dolcetti L, Serafini P, et al. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008; 222: 162-179.
135. Gabrilovich DI, Bronte V, Chen SH, et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007; 67(1): 425; author reply 6.
136. Haile LA, von Wasielewski R, Gamrekelashvili J, et al. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology 2008; 135(3): 871-881, 81 e1-e5.
137. Serafini P, Carbley R, Noonan KA, et al. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004; 64(17): 6337-6343.
138. Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 2006; 55(3): 237-245.
139. Sinha P, Okoro C, Foell D, et al. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 2008; 181(7): 4666-4675.
140. Youn JI, Nagaraj S, Collazo M, et al. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181(8): 5791-5802.
141. Movahedi K, Guilliams M, Van den Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111(8): 4233-4244.
142. Umemura N, Saio M, Suwa T, et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol 2008; 83(5): 1136-1144.
143. Gallina G, Dolcetti L, Serafini P, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006; 116(10): 2777-2790.
144. Rossner S, Voigtlander C, Wiethe C, et al. Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. Eur J Immunol 2005; 35(12): 3533-3544.
145. Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66(2): 1123-1131.
146. Mencacci A, Montagnoli C, Bacci A, et al. CD80+Gr-1+ myeloid cells inhibit development of antifungal Th1 immunity in mice with candidiasis. J Immunol 2002; 169(6): 3180-3190.
147. Yang R, Cai Z, Zhang Y, et al. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res 2006; 66(13): 6807-6815.
148. Filipazzi P, Valenti R, Huber V, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007; 25(18): 2546-2453.
149. Zea AH, Rodriguez PC, Atkins MB, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65(8): 3044-3048.
150. Mirza N, Fishman M, Fricke I, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006; 66(18): 9299-9307.
151. Srivastava MK, Bosch JJ, Thompson JA, et al. Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother 2008; 57(10): 1493-1504.
152. Hoechst B, Ormandy LA, Ballmaier M, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008; 135(1): 234-243.
153. Rodriguez PC, Zea AH, Culotta KS, et al. Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem 2002; 277(24): 21123-21129.
154. Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 2007; 109(4): 1568-1573.
155. Srivastava MK, Sinha P, Clements VK, et al. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 2010; 70(1): 68-77.
156. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007; 117(5): 1147-1154.
157. Rivoltini L, Carrabba M, Huber V, et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 2002; 188: 97-113.
158. Harari O, Liao JK. Inhibition of MHC II gene transcription by nitric oxide and antioxidants. Curr Pharm Des 2004; 10(8): 893-898.
159. Vickers SM, MacMillan-Crow LA, Green M, et al. Association of increased immunostaining for inducible nitric oxide synthase and nitrotyrosine with fibroblast growth factor transformation in pancreatic cancer. Arch Surg 1999; 134(3): 245-251.
160. Cobbs CS, Whisenhunt TR, Wesemann DR, et al. Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells. Cancer Res 2003; 63(24): 8670-8673.
161. Bentzen L, Keiding S, Horsman MR, et al. Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography--a study evaluating [18F]Fluoro-2-deoxy-D-glucose. Acta Oncol 2000; 39(5): 629-637.
162. Ekmekcioglu C, Mehrabi MR, Glogar HD, et al. Oxidized low-density lipoprotein is localized in the ventricles of hearts from patients with coronary heart disease. Int J Clin Lab Res 2000; 30(3): 133-140.
163. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. Clin Cancer Res 2006; 12(4): 1201-1207.
164. Nagaraj S, Gupta K, Pisarev V, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007; 13(7): 828-835.
165. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 2001; 61(12): 4756-4760.
166. Kusmartsev S, Nefedova Y, Yoder D, et al. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004; 172(2): 989-999.
167. Agostinelli E, Seiler N. Non-irradiation-derived reactive oxygen species (ROS) and cancer: therapeutic implications. Amino Acids 2006; 31(3): 341-355.
168. Hanson EM, Clements VK, Sinha P, et al. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol 2009; 183(2): 937-944.
169. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4(1): 71-78.
170. Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol 2009; 9(4): 259-270.
171. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008; 454(7203): 436-444.
172. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23(11): 549-555.
173. Mantovani A, Bottazzi B, Sozzani S, et al. Cytokine regulation of monocyte recruitment. Arch Immunol Ther Exp (Warsz) 1995; 43(2): 149-152.
174. Mantovani A, Bottazzi B, Colotta F, et al. The origin and function of tumor-associated macrophages. Immunol Today 1992; 13(7): 265-270.
175. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009; 27: 451-483.
176. Coussens LM, Tinkle CL, Hanahan D, et al. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000; 103(3): 481-490.
177. Torroella-Kouri M, Silvera R, Rodriguez D, et al. Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. Cancer Res 2009; 69(11): 4800-4809.
178. Biswas SK, Gangi L, Paul S, et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 2006; 107(5): 2112-2122.
179. Kool M, Soullie T, van Nimwegen M, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008; 205(4): 869-882.
180. Nakano H, Lin KL, Yanagita M, et al. Blood-derived inflammatory dendritic cells in lymph nodes stimulate acute T helper type 1 immune responses. Nat Immunol 2009; 10(4): 394-402.
181. Fong CH, Bebien M, Didierlaurent A, et al. An antiinflammatory role for IKKbeta through the inhibition of classical macrophage activation. J Exp Med 2008; 205(6): 1269-1276.
182. Murdoch C, Muthana M, Lewis CE. Hypoxia regulates macrophage functions in inflammation. J Immunol 2005; 175(10): 6257-6263.
183. Mancino A, Schioppa T, Larghi P, et al. Divergent effects of hypoxia on dendritic cell functions. Blood 2008; 112(9): 3723-3734.
184. Lewis C, Murdoch C. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol 2005; 167(3): 627-635.
185. Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 2008; 13 Suppl 3: 21-26.
186. Movahedi K, Laoui D, Gysemans C, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 2010; 70(14): 5728-5739.
187. Movahedi K, Schoonooghe S, Laoui D, et al. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res 2012; 72(16): 4165-4177.
188. Breckpot K, Bonehill A, Aerts J, et al. Dendritic Cells: Types, Life Cycles and Biological Functions (Cell Biology Research Progress). In: LC W, editor. Dendritic Cells: Types, Life Cycles and Biological Functions. 1st ed 2010.
189. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004; 4(12): 941-952.
190. Troy A, Davidson P, Atkinson C, et al. Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. J Urol 1998; 160(1): 214-219.
191. Troy AJ, Summers KL, Davidson PJ, et al. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res 1998; 4(3): 585-593.
192. Enk AH, Jonuleit H, Saloga J, et al. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 1997; 73(3): 309-316.
193. Nestle FO, Burg G, Fah J, et al. Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol 1997; 150(2): 641-651.
194. Chaux P, Favre N, Bonnotte B, et al. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression. A role in the immune tolerance to antigenic tumors. Adv Exp Med Biol 1997; 417: 525-528.
195. Chaux P, Favre N, Martin M, et al. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int J Cancer 1997; 72(4): 619-624.
196. Harding FA, McArthur JG, Gross JA, et al. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992; 356(6370): 607-609.
197. Davis CB, Gillies SD. Immunocytokines: amplification of anti-cancer immunity. Cancer Immunol Immunother 2003; 52(5): 297-308.
198. Collaborators MRCRC. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999; 353(9146): 14-17.
199. Brugmann A, Sorensen BS. Identifying responders to trastuzumab therapy in breast cancer. Future Oncol 2011; 7(6): 767-773.
200. Hodi FS. Overcoming immunological tolerance to melanoma: Targeting CTLA-4. Asia Pac J Clin Oncol 2010; 6 Suppl 1: S16-S23.
201. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8): 711-723.
202. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005; 23(35): 8968-8977.
203. Mkrtichyan M, Najjar YG, Raulfs EC, et al. Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J Immunol 2011; 41(10): 2977-2986.
204. Rosenblatt J, Glotzbecker B, Mills H, et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother 2011; 34(5): 409-418.
205. Wolchok JD, Yang AS, Weber JS. Immune regulatory antibodies: are they the next advance? Cancer J 2010; 16(4): 311-317.
206. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28(19): 3167-75.
207. Udyavar A, Geiger TL. Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy. Arch Immunol Ther Exp (Warsz) 2010; 58(5): 335-346.
208. Gattinoni L, Powell DJ, Jr, Rosenberg SA, et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006; 6(5): 383-393.
209. Ochi T, Fujiwara H, Yasukawa M. Application of adoptive T-cell therapy using tumor antigen-specific T-cell receptor gene transfer for the treatment of human leukemia. J Biomed Biotechnol 2010; 2010: 521248.
210. Myc LA, Gamian A, Myc A. Cancer vaccines. Any future? Arch Immunol Ther Exp (Warsz) 2011; 59(4): 249-259.
211. Scheibenbogen C, Letsch A, Schmittel A, et al. Rational peptide-based tumour vaccine development and T cell monitoring. Semin Cancer Biol 2003; 13(6): 423-429.
212. Morton DL, Hoon DS, Nizze JA, et al. Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. Ann N Y Acad Sci 1993; 690: 120-134.
213. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356(6365): 152-154.
214. Kreiter S, Selmi A, Diken M, et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 2010; 70(22): 9031-9040.
215. Van Lint S, Goyvaerts C, Maenhout S, et al. Preclinical evaluation of TriMix and antigen mRNA-based anti-tumour therapy. Cancer Res 2012; 72(7): 1661-1671.
216. Van Lint S, Thielemans K, Breckpot K. mRNA: delivering an antitumor message? Immunotherapy 2011; 3(5): 605-607.
217. Karanikas V, Lurquin C, Colau D, et al. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol 2003; 171(9): 4898-4904.
218. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5(4): 296-306.
219. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003; 15(2): 138-147.
220. Lurquin C, Lethe B, De Plaen E, et al. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 2005; 201(2): 249-257.
221. Tuyaerts S, Aerts JL, Corthals J, et al. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother 2007; 56(10): 1513-1537.
222. Turcotte S, Rosenberg SA. Immunotherapy for metastatic solid cancers. Adv Surg 2011; 45: 341-360.
223. Hershkovitz L, Schachter J, Treves AJ, Besser MJ. Focus on adoptive T cell transfer trials in melanoma. Clin Dev Immunol 2010; 2010: 260267.
224. Van Lint S, Van Nuffel A, Wilgenhof S, et al. Priming of cytotoxic T lymphocyte responses by dendritic cells: Induction of potent anti-tumor immune responses. In: Gotsiridze-Columbus N, editor. Cytotoxic T Lymphocytes: Mechanisms, Development and Disease: Nova publishers; in press.
225. Oshita C, Takikawa M, Kume A, et al. Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial. Oncol Rep 2012; 28(4): 1131-1138.
226. Mule JJ, Shu S, Schwarz SL, et al. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984; 225(4669): 1487-1489.
227. Averbook BJ, Wei JP, Perry-Lalley DM, et al. A tumor-elaborated supernatant factor chemotactic for IL-2 expanded tumor infiltrating T-lymphocytes. Lymphokine Cytokine Res 1993; 12(1): 1-8.
228. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988; 319(25): 1676-1680.
229. Cameron RB, Spiess PJ, Rosenberg SA. Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action. J Exp Med 1990; 171(1): 249-263.
230. Weber J, Atkins M, Hwu P, et al. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res 2011; 17(7): 1664-1673.
231. Besser MJ, Shapira-Frommer R, Treves AJ, et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 2010; 16(9): 2646-2455.
232. Kirkwood JM, Tarhini AA, Panelli MC, et al. Next generation of immunotherapy for melanoma. J Clin Oncol 2008; 26(20): 3445-3455.
233. Clay TM, Custer MC, Sachs J, et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 1999; 163(1): 507-513.
234. Kessels HW, Wolkers MC, van den Boom MD, et al. Immunotherapy through TCR gene transfer. Nat Immunol 2001; 2(10): 957-961.
235. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009; 21(2): 215-223.
236. Modlich U, Bohne J, Schmidt M, et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 2006; 108(8): 2545-2553.
237. Laufs S, Nagy KZ, Giordano FA, et al. Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns. Mol Ther 2004; 10(5): 874-881.
238. Stauss HJ, Thomas S, Cesco-Gaspere M, et al. WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells. Blood Cells Mol Dis 2008; 40(1): 113-116.
239. Bobisse S, Zanovello P, Rosato A. T-cell receptor gene transfer by lentiviral vectors in adoptive cell therapy. Expert Opin Biol Ther 2007; 7(6): 893-906.
240. Bobisse S, Rondina M, Merlo A, et al. Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors. Cancer Res 2009; 69(24): 9385-9394.
241. Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993; 90(2): 720-724.
242. Finney HM, Lawson AD, Bebbington CR, et al. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 1998; 161(6): 2791-2797.
243. Maher J, Brentjens RJ, Gunset G, et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol 2002; 20(1): 70-75.
244. Kowolik CM, Topp MS, Gonzalez S, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006; 66(22): 10995-11004.
245. Imai C, Mihara K, Andreansky M, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004; 18(4): 676-684.
246. Pule MA, Straathof KC, Dotti G, et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005; 12(5): 933-941.
247. Dotti G, Savoldo B, Brenner M. Fifteen years of gene therapy based on chimeric antigen receptors: are we nearly there yet?. Hum Gene Ther 2009; 20(11): 1229-1239.
248. Bonehill A, Heirman C, Tuyaerts S, et al. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol 2004; 172(11): 6649-6657.
249. Van Nuffel A, Benteyn D, Wilgenhof S, et al. Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients. Mol Ther 2012; 20(5): 1063-1074.
250. Ribas A. Genetically modified dendritic cells for cancer immunotherapy. Curr Gene Ther 2005; 5(6): 619-628.
251. Dullaers M, Thielemans K. From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy. J Gene Med 2006; 8(1): 3-17.
252. He Y, Zhang J, Mi Z, et al. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol 2005; 174(6): 3808-3817.
253. Pincha M, Sundarasetty BS, Stripecke R. Lentiviral vectors for immunization: an inflammatory field. Expert Rev Vaccines 2010; 9(3): 309-321.
254. Hu B, Tai A, Wang P. Immunization delivered by lentiviral vectors for cancer and infectious diseases. Immunol Rev 2011; 239(1): 45-61.
255. Metharom P, Ellem KA, Schmidt C, et al. Lentiviral vector-mediated tyrosinase-related protein 2 gene transfer to dendritic cells for the therapy of melanoma. Hum Gene Ther 2001; 12(18): 2203-2213.
256. Firat H, Zennou V, Garcia-Pons F, et al. Use of a lentiviral flap vector for induction of CTL immunity against melanoma. Perspectives for immunotherapy. J Gene Med 2002; 4(1): 38-45.
257. Wang B, He J, Liu C, et al. An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens. Vaccine 2006; 24(17): 3477-3489.
258. Dullaers M, Van Meirvenne S, Heirman C, et al. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther 2006; 13(7): 630-640.
259. Metharom P, Ellem KA, Wei MQ. Gene transfer to dendritic cells induced a protective immunity against melanoma. Cell Mol Immunol 2005; 2(4): 281-288.
260. Chapatte L, Colombetti S, Cerottini JC, et al. Efficient induction of tumor antigen-specific CD8+ memory T cells by recombinant lentivectors. Cancer Res 2006; 66(2): 1155-1160.
261. Esslinger C, Chapatte L, Finke D, et al. In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest 2003; 111(11): 1673-1681.
262. Kim JH, Majumder N, Lin H, et al. Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine. Hum Gene Ther 2005; 16(11): 1255-1266.
263. Palmowski MJ, Lopes L, Ikeda Y, et al. Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J Immunol 2004; 172(3): 1582-1587.
264. Finn OJ. Cancer immunology. N Engl J Med 2008; 358(25): 2704-2715.
265. Emeagi P, Van Lint S, Goyvaerts C, et al. Pro-inflammatory characteristics of SMAC/DIABLO-induced cell death in anti-tumor therapy. Cancer Res 2012; 72(6): 1342-1352.
266. Bourke MG, Salwa S, Harrington KJ, et al. The emerging role of viruses in the treatment of solid tumours. Cancer Treat Rev 2011; 37(8): 618-632.
267. Tay DL, Bhathal PS, Fox RM. Quantitation of G0 and G1 phase cells in primary carcinomas. Antibody to M1 subunit of ribonucleotide reductase shows G1 phase restriction point block. J Clin Invest 1991; 87(2): 519-527.
268. Lin YL, Desai A, Gesrson S. Lentiviruses: vectors for cancer gene therapy. In: Roth J, editor. Gene Based Therapies for Cancer, Current Cancer Research: Springer Science; 2010.
269. Bhaumik S. Advances in imaging gene-directed enzyme prodrug therapy. Curr Pharm Biotechnol 2011; 12(4): 497-507.
270. Cheng YC, Huang ES, Lin JC, et al. Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1. Proc Natl Acad Sci USA 1983; 80(9): 2767-2770.
271. Obaru K, Fujii S, Matsushita S, et al. Gene therapy for adult T cell leukemia using human immunodeficiency virus vector carrying the thymidine kinase gene of herpes simplex virus type 1. Hum Gene Ther 1996; 7(18): 2203-2208.
272. Loimas S, Toppinen MR, Visakorpi T, et al. Human prostate carcinoma cells as targets for herpes simplex virus thymidine kinase-mediated suicide gene therapy. Cancer Gene Ther 2001; 8(2): 137-144.
273. Pasanen T, Karppinen A, Alhonen L, et al. Polyamine biosynthesis inhibition enhances HSV-1 thymidine kinase/ganciclovir-mediated cytotoxicity in tumor cells. Int J Cancer 2003; 104(3): 380-388.
274. Gerolami R, Uch R, Faivre J, et al. Herpes simplex virus thymidine kinase-mediated suicide gene therapy for hepatocellular carcinoma using HIV-1-derived lentiviral vectors. J Hepatol 2004; 40(2): 291-297.
275. Ketola A, Maatta AM, Pasanen T, et al. Osteosarcoma and chondrosarcoma as targets for virus vectors and herpes simplex virus thymidine kinase/ganciclovir gene therapy. Int J Mol Med 2004; 13(5): 705-710.
276. Garcia-Rodriguez L, Abate-Daga D, Rojas A, et al. E-cadherin contributes to the bystander effect of TK/GCV suicide therapy and enhances its antitumoral activity in pancreatic cancer models. Gene Ther 2011; 18(1): 73-81.
277. Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res 2000; 60(15): 3989-3999.
278. Yang L, Chiang Y, Lenz HJ, et al. Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells. Hum Gene Ther 1998; 9(5): 719-728.
279. Cho HS, Lee HR, Kim MK. Bystander-mediated regression of murine neuroblastoma via retroviral transfer of the HSV-TK gene. J Korean Med Sci 2004; 19(1): 107-112.
280. Barba D, Hardin J, Sadelain M, et al. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 1994; 91(10): 4348-4352.
281. Stefani AL, Barzon L, Castagliuolo I, et al. Systemic efficacy of combined suicide/cytokine gene therapy in a murine model of hepatocellular carcinoma. J Hepatol 2005; 42(5): 728-735.
282. Guan J, Ma L, Wei L. Characteristics of ovarian cancer cells transduced by the bicistronic retroviral vector containing GM-CSF and HSV-TK genes. Chin Med J (Engl) 2001; 114(2): 147-151.
283. Yu D, Scott C, Jia WW, et al. Targeting and killing of prostate cancer cells using lentiviral constructs containing a sequence recognized by translation factor eIF4E and a prostate-specific promoter. Cancer Gene Ther 2006; 13(1): 32-43.
284. Deng LY, Wang JP, Gui ZF, et al. Antitumor activity of mutant bacterial cytosine deaminase gene for colon cancer. World J Gastroenterol 2011; 17(24): 2958-2964.
285. Cao G, Kuriyama S, Cui L, et al. Analysis of the human carcinoembryonic antigen promoter core region in colorectal carcinoma-selective cytosine deaminase gene therapy. Cancer Gene Ther 1999; 6(6): 572-580.
286. Yu ST, Li C, Lu MH, et al. Noninvasive and real-time monitoring of the therapeutic response of tumors in vivo with an optimized hTERT promoter. Cancer 2012; 118(7): 1884-1893.
287. Sato T, Neschadim A, Konrad M, et al. Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol Ther 2007; 15(5): 962-970.
288. Arnt CR, Chiorean MV, Heldebrant MP, et al. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem 2002; 277(46): 44236-44243.
289. Li L, Thomas RM, Suzuki H, et al. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 2004; 305(5689): 1471-1474.
290. Bockbrader KM, Tan M, Sun Y. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL-and etoposide-induced apoptosis in breast cancer cells. Oncogene 2005; 24(49): 7381-7388.
291. Vince JE, Wong WW, Khan N, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007; 131(4): 682-693.
292. McNeish IA, Bell S, McKay T, et al. Expression of Smac/DIABLO in ovarian carcinoma cells induces apoptosis via a caspase-9-mediated pathway. Exp Cell Res 2003; 286(2): 186-198.
293. Li R, Ruttinger D, Urba W, et al. Targeting and amplification of immune killing of tumor cells by pro-Smac. Int J Cancer 2004; 109(1): 85-94.
294. McNeish IA, Lopes R, Bell SJ, et al. Survivin interacts with Smac/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis. Exp Cell Res 2005; 302(1): 69-82.
295. Martinez-Ruiz G, Maldonado V, Ceballos-Cancino G, et al. Role of Smac/DIABLO in cancer progression. J Exp Clin Cancer Res 2008; 27: 48.
296. Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu Rev Immunol 1998; 16: 395-419.
297. Li XY, Lai YK, Zhang JF, et al. Lentivirus-mediated RNA interference targeting Bax inhibitor-1 suppresses ex vivo cell proliferation and in vivo tumor growth of nasopharyngeal carcinoma. Hum Gene Ther 2011; 22(10): 1201-1208.
298. Seo E, Kim S, Jho EH. Induction of cancer cell-specific death via MMP2 promoterdependent Bax expression. BMB Rep 2009; 42(4): 217-222.
299. Rangatia J, Bonnet D. Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation. Leukemia 2006; 20(1): 68-76.
300. Kim R. Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer 2005; 103(8): 1551-1560.
301. Kock N, Kasmieh R, Weissleder R, et al. Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. Neoplasia 2007; 9(5): 435-442.
302. Zhang X, Zhao L, Chen C, et al. The effect of lentivirus-mediated expression of tumor necrosis factor related apoptosis-inducing ligand and shRNA against Bcl-2 on the growth of lymphoma cells. Leuk Lymphoma 2012; 53(4): 710-717.
303. Wenger T, Mattern J, Haas TL, et al. Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and -independent effects. Cancer Gene Ther 2007; 14(3): 316-326.
304. Wenger T, Mattern J, Penzel R, et al. Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors. Cell Death Differ 2006; 13(10): 1740-1751.
305. Benard J, Douc-Rasy S, Ahomadegbe JC. TP53 family members and human cancers. Hum Mutat 2003; 21(3): 182-191.
306. Cai DW, Mukhopadhyay T, Liu Y, et al. Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum Gene Ther 1993; 4(5): 617-624.
307. Fujiwara T, Grimm EA, Mukhopadhyay T, et al. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 1993; 53(18): 4129-4133.
308. Goyette MC, Cho K, Fasching CL, et al. Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer. Mol Cell Biol 1992; 12(3): 1387-1395.
309. Kaeser MD, Pebernard S, Iggo RD. Regulation of p53 stability and function in HCT116 colon cancer cells. J Biol Chem 2004; 279(9): 7598-7605.
310. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007; 13(1): 23-31.
311. Van Maerken T, Speleman F, Vermeulen J, et al. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res 2006; 66(19): 9646-9655.
312. Durual S, Rideau A, Ruault-Jungblut S, et al. Lentiviral PU.1 overexpression restores differentiation in myeloid leukemic blasts. Leukemia 2007; 21(5): 1050-9.
313. Li L, Li B, Zhang H, et al. Lentiviral vector-mediated PAX6 overexpression promotes growth and inhibits apoptosis of human retinoblastoma cells. Invest Ophthalmol Vis Sci 2011; 52(11): 8393-8400.
314. Locher C, Conforti R, Aymeric L, et al. Desirable cell death during anticancer chemotherapy. Ann N Y Acad Sci 2010; 1209: 99-108.
315. Kepp O, Tesniere A, Schlemmer F, et al. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 2009; 14(4): 364-375.
316. Tesniere A, Apetoh L, Ghiringhelli F, et al. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 2008; 20(5): 504-511.
317. Tesniere A, Panaretakis T, Kepp O, et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2008; 15(1): 3-12.
318. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002; 20(9): 2388-2399.
319. Dingli D, Russell SJ, Morris JC, 3rd. In vivo imaging and tumor therapy with the sodium iodide symporter. J Cell Biochem 2003; 90(6): 1079-1086.
320. Kim HJ, Jeon YH, Kang JH, et al. In vivo long-term imaging and radioiodine therapy by sodium-iodide symporter gene expression using a lentiviral system containing ubiquitin C promoter. Cancer Biol Ther 2007; 6(7): 1130-1135.
321. Ke CC, Hsieh YJ, Hwu L, et al. Evaluation of lentiviral-mediated expression of sodium iodide symporter in anaplastic thyroid cancer and the efficacy of in vivo imaging and therapy. J Oncol 2011; 2011: 178967.
322. Chen L, Guo G, Liu T, et al. Radiochemotherapy of hepatocarcinoma via lentivirus-mediated transfer of human sodium iodide symporter gene and herpes simplex virus thymidine kinase gene. Nucl Med Biol 2011; 38(5): 757-763.
323. Bardella C, Dettori D, Olivero M, et al. The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo. Clin Cancer Res 2007; 13(7): 2191-2198.
324. Wang Y, Adachi Y, Imsumran A, et al. Targeting for insulinlike growth factor-I receptor with short hairpin RNA for human digestive/gastrointestinal cancers. J Gastroenterol 2010; 45(2): 159-170.
325. Song X, Liu X, Chi W, et al. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol 2006; 58(6): 776-784.
326. Chinnasamy D, Fairbairn LJ, Neuenfeldt J, et al. Lentivirus-mediated expression of mutant MGMTP140K protects human CD34+ cells against the combined toxicity of O6-benzylguanine and 1,3-bis(2-chloroethyl)-nitrosourea or temozolomide. Hum Gene Ther 2004; 15(8): 758-769.
327. Zielske SP, Gerson SL. Lentiviral transduction of P140K MGMT into human CD34(+) hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro. Mol Ther 2002; 5(4): 381-387.
328. Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin Cancer Res 2006; 12(2): 328-331.
329. Milsom MD, Williams DA. Live and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection. DNA Repair (Amst) 2007; 6(8): 1210-1221.
330. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82(1): 4-6.
331. Liu Y, Deisseroth A. Tumor vascular targeting therapy with viral vectors. Blood 2006; 107(8): 3027-3033.
332. Pfeifer A, Kessler T, Silletti S, et al. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc Natl Acad Sci USA 2000; 97(22): 12227-12232.
333. Shichinohe T, Bochner BH, Mizutani K, et al. Development of lentiviral vectors for antiangiogenic gene delivery. Cancer Gene Ther 2001; 8(11): 879-889.
334. Guo SW, Che HM, Li WZ. Anti-tumor effect of lentivirus-mediated gene transfer of alphastatin on human glioma. Cancer Sci 2011; 102(5): 1038-1044.
335. Shiau AL, Teo ML, Chen SY, et al. Inhibition of experimental lung metastasis by systemic lentiviral delivery of kallistatin. BMC Cancer 2010; 10: 245.
336. De Palma M, Venneri MA, Naldini L. In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum Gene Ther 2003; 14(12): 1193-1206.
337. Baskar S. Gene-modified tumor cells as cellular vaccine. Cancer Immunol Immunother 1996; 43(3): 165-173.
338. Koya RC, Kasahara N, Pullarkat V, et al. Transduction of acute myeloid leukemia cells with third generation self-inactivating lentiviral vectors expressing CD80 and GM-CSF: effects on proliferation, differentiation, and stimulation of allogeneic and autologous anti-leukemia immune responses. Leukemia 2002; 16(9): 1645-1654.
339. Stripecke R, Cardoso AA, Pepper KA, et al. Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage-colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses. Blood 2000; 96(4): 1317-1326.
340. Stripecke R, Levine AM, Pullarkat V, et al. Immunotherapy with acute leukemia cells modified into antigen-presenting cells: ex vivo culture and gene transfer methods. Leukemia 2002; 16(10): 1974-1983.
341. Redell MS, Tweardy DJ. Targeting transcription factors for cancer therapy. Curr Pharm Des 2005; 11(22): 2873-2887.
342. Perkins ND. NF-kappaB: tumor promoter or suppressor? Trends Cell Biol 2004; 14(2): 64-69.
343. Bhaumik D, Scott GK, Schokrpur S, et al. Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 2008; 27(42): 5643-5647.
344. Wu GQ, Liao YJ, Qin ZQ, et al. PYRIN domain of NALP2 inhibits cell proliferation and tumor growth of human glioblastoma. Plasmid 2010; 64(1): 41-50.
345. Li GH, Wei H, Chen ZT, et al. STAT3 silencing with lentivirus inhibits growth and induces apoptosis and differentiation of U251 cells. J Neurooncol 2009; 91(2): 165-174.
346. Li GH, Wei H, Lv SQ, et al. Knockdown of STAT3 expression by RNAi suppresses growth and induces apoptosis and differentiation in glioblastoma stem cells. Int J Oncol 2010; 37(1): 103-110.
347. Ma LD, Zhou M, Wen SH, et al. Effects of STAT3 silencing on fate of chronic myelogenous leukemia K562 cells. Leuk Lymphoma 2010; 51(7): 1326-1336.
348. Li H, Huang C, Huang K, et al. STAT3 knockdown reduces pancreatic cancer cell invasiveness and matrix metalloproteinase-7 expression in nude mice. PLoS One 2011; 6(10): e25941.
349. Qian WF, Guan WX, Gao Y, et al. Inhibition of STAT3 by RNA interference suppresses angiogenesis in colorectal carcinoma. Braz J Med Biol Res 2011; 44(12): 1222-1230.
350. Emeagi P.U., Maenhout S, Dang N, et al. Down-regulation of Stat3 in melanoma: reprogramming the immune microenvi-ronment as an anti-cancer therapeutic strategy. Gene Ther 2013; Accepted for publication.
351. Pauwels K, Gijsbers R, Toelen J, et al. State-of-the-art lentiviral vectors for research use: risk assessment and biosafety recommendations. Curr Gene Ther 2009; 9(6): 459-474.
352. Cattoglio C, Facchini G, Sartori D, et al. Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood 2007; 110(6): 1770-1778.
353. Somia N, Verma IM. Gene therapy: trials and tribulations. Nat Rev Genet 2000; 1(2): 91-99.
354. Yu D, Chen D, Chiu C, et al. Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther 2001; 8(9): 628-635.
355. Petrigliano FA, Virk MS, Liu N, et al. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter. Prostate 2009; 69(13): 1422-1434.
356. Uch R, Gerolami R, Faivre J, et al. Hepatoma cell-specific ganciclovir-mediated toxicity of a lentivirally transduced HSV-TkEGFP fusion protein gene placed under the control of rat alpha-fetoprotein gene regulatory sequences. Cancer Gene Ther 2003; 10(9): 689-695.
357. Badr CE, Niers JM, Morse D, et al. Suicidal gene therapy in an NF-kappaB-controlled tumor environment as monitored by a secreted blood reporter. Gene Ther 2011; 18(5): 445-451.
358. Morizono K, Xie Y, Ringpis GE, et al. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med 2005; 11(3): 346-352.
359. Chadwick MP, Morling FJ, Cosset FL, et al. Modification of retroviral tropism by display of IGF-I. J Mol Biol 1999; 285(2): 485-494.
360. Somia NV, Zoppe M, Verma IM. Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. Proc Natl Acad Sci USA 1995; 92(16): 7570-7574.
361. Boerger AL, Snitkovsky S, Young JA. Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types. Proc Natl Acad Sci USA 1999; 96(17): 9867-9872.
362. Chandrashekran A, Gordon MY, Casimir C. Targeted retroviral transduction of c-kit+ hematopoietic cells using novel ligand display technology. Blood 2004; 104(9): 2697-2703.
363. Lin AH, Kasahara N, Wu W, et al. Receptor-specific targeting mediated by the coexpression of a targeted murine leukemia virus envelope protein and a binding-defective influenza hemagglutinin protein. Hum Gene Ther 2001; 12(4): 323-332.
364. Yang L, Bailey L, Baltimore D, et al. Targeting lentiviral vectors to specific cell types in vivo. Proc Natl Acad Sci USA 2006; 103(31): 11479-11484.
365. Froelich S, Tai A, Wang P. Lentiviral vectors for immune cells targeting. Immunopharmacol Immunotoxicol 2010; 32(2): 208-218.
366. Gainkam LO, Huang L, Caveliers V, et al. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med 2008; 49(5): 788-795.
367. Vaneycken I, Devoogdt N, Van Gassen N, et al. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J 2011; 25(7): 2433-2446.
368. Vosjan MJ, Vercammen J, Kolkman JA, et al. Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy. Mol Cancer Ther 2012; 11(4): 1017-1025.
369. Vaneycken I, Govaert J, Vincke C, et al. In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT. J Nucl Med 2010; 51(7): 1099-1106.
370. Pariente N, Morizono K, Virk MS, et al. A novel dual-targeted lentiviral vector leads to specific transduction of prostate cancer bone metastases in vivo after systemic administration. Mol Ther 2007; 15(11): 1973-1981.
371. Hayward WS, Neel BG, Astrin SM. Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis. Nature 1981; 290(5806): 475-480.
372. Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990; 323(9): 570-578.
373. Gaspar HB, Parsley KL, Howe S, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004; 364(9452): 2181-2187.
374. Ginn SL, Curtin JA, Kramer B, et al. Treatment of an infant with X-linked severe combined immunodeficiency (SCID-X1) by gene therapy in Australia. Med J Aust 2005; 182(9): 458-463.
375. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348(3): 255-256.